ArticleJAC-antimicrobial resistance2025
Antibiotic treatment duration for isolated methicillin-susceptible
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MSSA tricuspid valve infective endocarditis (TVIE) is associated with significant morbidity and there is not consensus surrounding the optimal duration of antibiotic therapy. We report the outcomes of treating MSSA TVIE endocarditis using a multidisciplinary team and cardiovascular infectious diseases consult service. Methods: Patients were identified from the multidisciplinary endocarditis team registry in a single-centre retrospective study. Results: Between 7 September 2021 and 7 September 2024, 34 patients, including 27 who inject drugs, with isolated native MSSA TVIE were identified. Patients received a median of 28 days (IQR 11-41) of antibiotics and 50% transitioned to oral antibiotics for a median of 14 days. There was one relapsed infection (2.9%) and one death at 90 days (2.9%). There was no difference in relapsed infection or mortality at 90 days for patients transitioned to oral therapy compared with IV ( Conclusions: With a standardized approach to patient care, including a cardiovascular infectious diseases consult service and multidisciplinary team, patients with MSSA isolated TVIE without metastatic osteoarticular or spinal infections were successfully treated with antibiotic courses of ≤28 days with low rates of mortality and relapsed infection at 90 days.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.